Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Change in Accured Expenses: 2012-2025

Historic Change in Accured Expenses for Sunshine Biopharma (SBFM) over the last 11 years, with Sep 2025 value amounting to $1.2 million.

  • Sunshine Biopharma's Change in Accured Expenses rose 316.50% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 46.59%. This contributed to the annual value of $4.0 million for FY2024, which is 392.04% up from last year.
  • Per Sunshine Biopharma's latest filing, its Change in Accured Expenses stood at $1.2 million for Q3 2025, which was up 436.76% from -$363,693 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Change in Accured Expenses ranged from a high of $2.9 million in Q4 2022 and a low of -$1.0 million during Q2 2023.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$73,661 (2023), whereas its average is $272,245.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 10,263.39% in 2022, then slumped by 10,997.79% in 2023.
  • Quarterly analysis of 5 years shows Sunshine Biopharma's Change in Accured Expenses stood at -$28,749 in 2021, then soared by 10,263.39% to $2.9 million in 2022, then tumbled by 126.56% to -$776,161 in 2023, then soared by 326.07% to $1.8 million in 2024, then skyrocketed by 316.50% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, -$363,693 for Q2 2025, and -$486,009 during Q1 2025.